Navigation Links
DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC

. In extremely minute quantities, botulinum toxin can be used therapeutically, as for the cosmetic use of Botox®, a commercial preparation of serotype A botulinum toxin, but the effects of the neurotoxin are extremely long lasting and paralytic at higher than therapeutic doses.

About Botulinum Toxin Vaccines

Vaccination is considered the best option to prevent neurological effects of toxin exposure. Because of the rarity of the natural disease, a vaccine would not be used in mass population immunization programs unless they were actually used or a significant threat. In that event, the vaccine would have to be made available for widespread dissemination for rapid and convenient vaccination of a large population. The only vaccine available is an experimental vaccine based on inactivation of a mixture of serotypes of the natural toxins that is given by injection, is not licensed by the FDA and cannot be used for widespread immunization. New multivalent vaccines based on non-toxic subunits are being developed, including BT-VACC™.

About DOR BioPharma, Inc.

DOR BioPharma, Inc. is a biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal ("GI") diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally acting corticosteroid being developed for the treatment of GI graft-versus-host disease ("GVHD"), a common and potentially life-threatening complication of bone marrow transplantation. DOR has filed an NDA with the FDA for the treatment of GI GVHD, and has received a PDUFA date of July 21, 2007. An MAA with the EMEA for orBec® has also been filed and validated. orBec® may also have application in treating other gastrointestinal disorders characterized by severe inflammation. DOR has also recently initiated a clinical development program with its Lipid Polymer Micelle
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
4. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:2/27/2015)... 27, 2015 Roughly three-quarters of pharmacists ... substituting an interchangeable biosimilar for its branded biologic ... nonproprietary name, according to a survey published in ... Journal of Managed Care & Specialty Pharmacy (JMCP). ... of pharmacists would feel as confident if the ...
(Date:2/27/2015)... Feb. 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... pre-clinical study published in the Proceedings of ... ) that showed when ibrutinib (IMBRUVICA ® ) ... inhibitor), suppression of tumor growth was enhanced suggesting ... certain hematologic cancers and solid tumors with the ...
(Date:2/27/2015)... Feb. 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... both its pro forma net operating loss (NOL) guidance ... strong financial position.  Isis, significantly improved financial results were ... million in payments the Company received from its partners.  ... was a nearly 60% improvement over its 2013 NOL ...
Breaking Medicine Technology:Survey Published in AMCP's JMCP Finds Pharmacists Are Most Confident Substituting Interchangeable Biosimilars for Brand Biologics When Products Share Nonproprietary Name 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17
... DALLAS, Oct. 15 /PRNewswire-FirstCall/ -- ACCESS ... provided an update on its European commercial launch of ... debilitating side effect of radiation treatment and chemotherapy. ... five European countries, having been granted the CE mak ...
... Pharmaceuticals, Inc. announced today that new data confirm that ... of fat absorption in children aged 7-11 years who ... (CF). EPI is a condition resulting from a deficiency ... are necessary to digest nutrients in food. CREON® has ...
Cached Medicine Technology:Access Pharmaceuticals Provides Update on MuGard Commercial Launch and First European Clinicians Feedback 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch and First European Clinicians Feedback 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch and First European Clinicians Feedback 4CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 2CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 3CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 4CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 5CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 6
(Date:3/1/2015)... 02, 2015 As residents and ... co-founders, Michael Burns and Carita Weaver, believe in ... working with the Southlake Chamber of Commerce, Carroll ... works recently launched a website for Southlake mayoral ... primary communications tool for Hill’s campaign, the website ...
(Date:3/1/2015)... 01, 2015 Adults who are not ... for term or universal policies can now use the ... best life insurance companies for single adults can now ... http://quotespros.com/life-insurance.html . , The rate plans that nationwide ... tied to a number of life protection policies. The ...
(Date:3/1/2015)... NY (PRWEB) March 01, 2015 The ... grown substantially over the past few weeks in two ... are actively filing claims, the Firm announces. , ... 7,713 cases in the Bergen County proceeding established for ... compared with a few weeks earlier, when 90 fewer ...
(Date:3/1/2015)... Theme and plugin developers from Pixel ... pack for Final Cut Pro X entitled Transccordion. , ... any FCPX editors project.” Said Christiana Austin, CEO of ... needed to easily drag and drop their accordion transition ... different controls over the parameters of this transition bundle ...
(Date:2/28/2015)... Heart diseases are on the rise in ... adult population and 5 percent of rural adult population ... percent of them require specialized investigation and treatment to ... diseases (CVD). , A division of Indian Business News ... titled “Indian Coronary Stent Market Forecast to 2019”. The ...
Breaking Medicine News(10 mins):Health News:Website Launched for Southlake, Texas Mayoral Candidate Laura Hill 2Health News:Best Life Insurance Companies for Single Adults Now Searchable at Insurance Website 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3
... help improve treatment for psychiatric problems , , MONDAY, ... have an increased risk of developing schizophrenia, depression, generalized ... new study that spanned more than three decades shows. ... persistent depression and anxiety, as well as an increased ...
... Dec. 1 Amanzi Tea ( www.amanzitea.com ), a unique tea ... Manhattan location opening Saturday, December 6th, it is offering free "amanzi ... on Saturdays, December 6th, 13th and 20th from noon until four. ... immune system with the onset of winter. , ...
... As part of the Dec. 1 observance of World AIDS Day, ... tested for HIV - the virus that causes AIDS. He also ... how it is prevented. , , ... or race, being tested for HIV is the only sure way ...
... CT can effectively assess coronary artery stenosis, according to ... in Leiden, The Netherlands. , The study consisted ... with 50% or more stenosis. 10,561 coronary artery segments ... sensitivity rate for detecting significant coronary artery stenosis in ...
... studies have shown that babies exposed to tobacco in ... weight and are at increased risk for sudden infant ... reveals that these babies are also less likely to ... whose mothers did not smoke during pregnancy. , Researchers ...
... Dec. 1 As President Bush seeks,to push through ... especially,adversely impact healthcare services and workplace safety, the California,Nurses ... web browsers to help "send Bush packing,", http://www.SendBushPacking.com . ... offers an interactive game highlighting some of the "midnight,rules" ...
Cached Medicine News:Health News:Low Childhood IQ Tied to Risk of Later Mental Disorders 2Health News:Amanzi Tea offers free, natural 'Flu Shots' to New Yorkers 2Health News:PA Department of Health Recognizes 20th Anniversary of World AIDS Day; Urges HIV Testing 2Health News:Newborns exposed to maternal smoking more irritable, difficult to soothe 2Health News:Citing 'Midnight Rules' to Erode Health and Safety, Nurses Unveil New Website to Send Bush Packing 2
... flexible liquid handling system ... functionality of up to ... on the same worksurface. ... smart solutions for targeted ...
... award winning practically new Dade DAC II automatic ... automatic cell washer. The Dade (Baxter) Dac II ... primarily used to process samples for immunohematolgy tests. ... bench-top multipurpose instrument , Performs cell washing and ...
... a simple click of the mouse ... mouse cursor to the desired position ... slide and the magnified image is ... Interface (GUI) enables one-click operation of ...
... floor-standing centrifuge. Mobile space saver, very ... of accessories, analog controls, large bright ... (JOUAN patented pendulum system), guard barrier, ... limitation, rugged motor, tough steel casing ...
Medicine Products: